Literature DB >> 22072723

The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

José-Carlos Fernandez1, Agnès Billecocq, Jean Paul Durand, Catherine Cêtre-Sossah, Eric Cardinale, Philippe Marianneau, Michel Pépin, Noël Tordo, Michèle Bouloy.   

Abstract

Rift Valley fever (RVF) is an emerging zoonosis in Africa which has spread to Egypt, the Arabian Peninsula, Madagascar, and Comoros. RVF virus (RVFV) (Bunyaviridae family, Phlebovirus genus) causes a wide range of symptoms in humans, from benign fever to fatal hemorrhagic fever. Ruminants are severely affected by the disease, which leads to a high rate of mortality in young animals and to abortions and teratogenesis in pregnant females. Diagnostic tests include virus isolation and genome or antibody detection. During RVFV infection, the nucleoprotein encapsidating the tripartite RNA genome is expressed in large amounts and raises a robust antibody response, while the envelope glycoproteins elicit neutralizing antibodies which play a major role in protection. Much less is known about the antigenicity/immunogenicity of the nonstructural protein NSs, which is a major virulence factor. Here we have developed a competitive enzyme-linked immunosorbent assay (ELISA) enabling detection of low levels of NSs-specific antibodies in naturally infected or vaccinated ruminants. Detection of the NSs antibodies was validated by Western blotting. Altogether, our data showed that the NSs antibodies were detected in only 55% of animals naturally infected by RVFV, indicating that NSs does not induce a consistently high immune response. These results are discussed in light of differentiation between infected and vaccinated animals (DIVA) tests distinguishing naturally infected animals and those vaccinated with NSs-defective vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072723      PMCID: PMC3255954          DOI: 10.1128/CVI.05420-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  36 in total

Review 1.  Rift Valley fever virus.

Authors:  Brian H Bird; Thomas G Ksiazek; Stuart T Nichol; N James Maclachlan
Journal:  J Am Vet Med Assoc       Date:  2009-04-01       Impact factor: 1.936

2.  Outbreak news. Rift Valley fever, Madagascar.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-05-02

3.  NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase.

Authors:  Matthias Habjan; Andreas Pichlmair; Richard M Elliott; Anna K Overby; Timo Glatter; Matthias Gstaiger; Giulio Superti-Furga; Hermann Unger; Friedemann Weber
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

4.  Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo.

Authors:  Janusz T Paweska; Petrus Jansen van Vuren; Alan Kemp; Peter Buss; Roy G Bengis; Francis Gakuya; Robert F Breiman; M Kariuki Njenga; Robert Swanepoel
Journal:  Vet Microbiol       Date:  2007-08-17       Impact factor: 3.293

5.  RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses.

Authors:  Agnès Billecocq; Nicolas Gauliard; Nicolas Le May; Richard M Elliott; Ramon Flick; Michèle Bouloy
Journal:  Virology       Date:  2008-07-09       Impact factor: 3.616

6.  Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA.

Authors:  P Jansen van Vuren; J T Paweska
Journal:  J Virol Methods       Date:  2009-01-20       Impact factor: 2.014

7.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

8.  Development of a RVFV ELISA that can distinguish infected from vaccinated animals.

Authors:  Anita K McElroy; César G Albariño; Stuart T Nichol
Journal:  Virol J       Date:  2009-08-13       Impact factor: 4.099

9.  Rift Valley fever, Mayotte, 2007-2008.

Authors:  Daouda Sissoko; Claude Giry; Philippe Gabrie; Arnaud Tarantola; François Pettinelli; Louis Collet; Eric D'Ortenzio; Philippe Renault; Vincent Pierre
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

10.  A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells.

Authors:  Nicolas Le May; Zeyni Mansuroglu; Psylvia Léger; Thibaut Josse; Guillaume Blot; Agnès Billecocq; Ramon Flick; Yves Jacob; Eliette Bonnefoy; Michèle Bouloy
Journal:  PLoS Pathog       Date:  2008-01       Impact factor: 6.823

View more
  7 in total

1.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

2.  Evaluation of Fluorescence Microsphere Immunoassay for Detection of Antibodies to Rift Valley Fever Virus Nucleocapsid Protein and Glycoproteins.

Authors:  I K Ragan; A S Davis; D S McVey; J A Richt; R R Rowland; W C Wilson
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

3.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

4.  Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.

Authors:  Sabarish V Indran; Olga A Lihoradova; Inaia Phoenix; Nandadeva Lokugamage; Birte Kalveram; Jennifer A Head; Bersabeh Tigabu; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Gen Virol       Date:  2013-03-20       Impact factor: 3.891

5.  Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells.

Authors:  Hana M Weingartl; Shunzhen Zhang; Peter Marszal; Alan McGreevy; Lynn Burton; William C Wilson
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

6.  A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus.

Authors:  Elizabeth R Allen; Stefanie A Krumm; Jayna Raghwani; Steinar Halldorsson; Angela Elliott; Victoria A Graham; Elina Koudriakova; Karl Harlos; Daniel Wright; George M Warimwe; Benjamin Brennan; Juha T Huiskonen; Stuart D Dowall; Richard M Elliott; Oliver G Pybus; Dennis R Burton; Roger Hewson; Katie J Doores; Thomas A Bowden
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

7.  Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Authors:  William C Wilson; Bonto Faburay; Jessie D Trujillo; Izabela Ragan; Sun-Young Sunwoo; Igor Morozov; Vinay Shivanna; Aaron Balogh; Kinga Urbaniak; D Scott McVey; Dashzeveg Bold; Natasha N Gaudreault; Erin E Schirtzinger; Wenjun Ma; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2021-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.